Presentation and Outcomes of Hepatocellular Carcinoma in the Arabian Peninsula: A Review of a Single Institution Experience in the Sorafenib Era.
Aged
Carcinoma, Hepatocellular
/ diagnosis
Diabetes Mellitus
/ epidemiology
Disease Progression
Female
Follow-Up Studies
Hepatitis C, Chronic
/ epidemiology
Humans
Kaplan-Meier Estimate
Kuwait
/ epidemiology
Liver
/ pathology
Liver Cirrhosis
/ diagnosis
Liver Neoplasms
/ diagnosis
Male
Middle Aged
Prognosis
Retrospective Studies
Risk Factors
Severity of Illness Index
Sex Factors
Sorafenib
/ therapeutic use
Treatment Outcome
Arabian Peninsula
Hepatocellular carcinoma
Sorafenib
Journal
Journal of gastrointestinal cancer
ISSN: 1941-6636
Titre abrégé: J Gastrointest Cancer
Pays: United States
ID NLM: 101479627
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
pubmed:
7
12
2019
medline:
22
6
2021
entrez:
7
12
2019
Statut:
ppublish
Résumé
There is a growing evidence showing that there are geographic differences in hepatocellular carcinoma (HCC). Little is known about the characteristics of hepatocellular carcinoma in the Arabian Peninsula. The present study examines the presentation and outcomes of HCC in a single institution. A retrospective chart review of patients presented with advanced-stage HCC to Kuwait Cancer Control Center (KCCC) between 2008 and 2018 was conducted. Data collected included patients demographics, HCC risk factors, performance status, Child-Pugh score, pick up of sorafenib, and survival. About 111 cases were analyzed. The mean age of the cohort was 61.8 ± 11.4 years and 94 patients (84.7%) were males. HCV and diabetes were the most common risk factors for HCC and presented in 60 patients (54.1%) and 45 patients (40.5%), respectively. About 78 (70.3%) patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 at presentation. Only 29 (26.1%) patients presented with Child-Pugh class A, while 42 (40.4%) patients received sorafenib. The median overall survival was only 3 months. In our cohort, HCV and diabetes were the main risk factors for HCC. The majority of patients was not amenable to sorafenib treatment and carries a very poor prognosis.
Identifiants
pubmed: 31808059
doi: 10.1007/s12029-019-00341-7
pii: 10.1007/s12029-019-00341-7
doi:
Substances chimiques
Sorafenib
9ZOQ3TZI87
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
85-89Références
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.
doi: 10.3322/canjclin.55.2.74
Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533–43.
doi: 10.1016/S1470-2045(01)00486-7
Rasul KI, Al-Azawi SH, Chandra P, Abou-Alfa GK, Knuth A. Status of hepatocellular carcinoma in Gulf region. Chin Clin Oncol. 2013;2(4).
Takayama T, Makuuchi M, Kojiro M, Lauwers GY, Adams RB, Wilson SR, et al. Early hepatocellular carcinoma: pathology, imaging, and therapy. Ann Surg Oncol. 2008;15(4):972–8.
doi: 10.1245/s10434-007-9685-0
Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S, et al. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol. 1999;58(3):201–7.
doi: 10.1002/(SICI)1096-9071(199907)58:3<201::AID-JMV3>3.0.CO;2-2
Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118(12):3030–44.
doi: 10.1002/ijc.21731
Ezzat S, Abdel-Hamid M, Eissa SA-L, Mokhtar N, Labib NA, El-Ghorory L, et al. Associations of pesticides, HCV, HBV, and hepatocellular carcinoma in Egypt. Int J Hyg Environ Health. 2005;208(5):329–39.
doi: 10.1016/j.ijheh.2005.04.003
El-Sayed H, Abaza S, Mehanna S, Winch PJ. The prevalence of hepatitis B and C infections among immigrants to a newly reclaimed area endemic for Schistosoma mansoni in Sinai. Egypt Acta Trop. 1997;68(2):229–37.
doi: 10.1016/S0001-706X(97)00097-1
Fakeeh M, Zaki AM. Hepatitis C: prevalence and common genotypes among ethnic groups in Jeddah, Saudi Arabia. Am J Trop Med Hyg. 1999;61(6):889–92.
doi: 10.4269/ajtmh.1999.61.889
Baffy G. 2012 hepatocellular carcinoma in type 2 diabetes: more than meets the eye. Nature Publishing Group.
Salmon D, Bani-Sadr F, Loko M-A, Stitou H, Gervais A, Durant J, et al. Insulin resistance is associated with a higher risk of hepatocellular carcinoma in cirrhotic HIV/HCV-co-infected patients: results from ANRS CO13 HEPAVIH. J Hepatol. 2012;56(4):862–8.
doi: 10.1016/j.jhep.2011.11.009
Wang P, Kang D, Cao W, Wang Y, Liu Z. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2012;28(2):109–22.
doi: 10.1002/dmrr.1291
Wang Y-G, Wang P, Wang B, Fu Z-J, Zhao W-J, Yan S-L. Diabetes mellitus and poorer prognosis in hepatocellular carcinoma: a systematic review and meta-analysis. mn PLoS One. 2014;9(5):e95485.
doi: 10.1371/journal.pone.0095485
Qian G-S, Ross RK, Yu MC, Yuan J-M, Gao Y-T, Henderson BE, et al. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People’s Republic of China. Cancer Epidemiol Biomarkers Prev. 1994;3(1):3–10.
pubmed: 8118382
Yu M-W, Yang Y-C, Yang S-Y, Cheng S-W, Liaw Y-F, Lin S-M, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case–control study among men. J Natl Cancer Inst. 2001;93(21):1644–51.
doi: 10.1093/jnci/93.21.1644
Poustchi H, Sepanlou SG, Esmaili S, Mehrabi N, Ansarymoghadam A. Hepatocellular carcinoma in the world and the Middle East. Middle East J Dig Dis. 2010;2(1):31.
pubmed: 25197510
pmcid: 4154905
Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005;100(12):2708.
doi: 10.1111/j.1572-0241.2005.00289.x
Wayne JD, Lauwers GY, Ikai I, Doherty DA, Belghiti J, Yamaoka Y, et al. Preoperative predictors of survival after resection of small hepatocellular carcinomas. Ann Surg. 2002;235(5):722.
doi: 10.1097/00000658-200205000-00015
Natsuizaka M, Omura T, Akaike T, Kuwata Y, Yamazaki K, Sato T, et al. Clinical features of hepatocellular carcinoma with extrahepatic metastases. J Gastroenterol Hepatol. 2005;20(11):1781–7.
doi: 10.1111/j.1440-1746.2005.03919.x
Wu Q, Qin S-K. Features and treatment options of Chinese hepatocellular carcinoma. Chin Clin Oncol. 2013;2(4).
Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
doi: 10.1016/S1470-2045(08)70285-7